Últimas noticias sobre Veru (NASDAQ:VERU) Bolsa

VERU INC

Veru

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

Veru Inc

VERUS INTL INC by Verus International, Inc.

Verus International Inc

VerusCoin

News

General

ZENA

ZenaTech Shares Halted On Circuit Breaker To The Downside, Stock Now Up 76.4%

B of A Securities analyst Omar Dessouky maintains Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Buy and raises the price target from $86 to $103.

Price Target

Analyst Ratings

RBLX

B of A Securities Maintains Buy on Roblox, Raises Price Target to $103

Macro Economic Events

Economics

Reuters Cites Filing With Commerce Department Saying Delta Air Lines Says New U.S. Aviation Tariffs Could Force Company To Stop Taking Deliveries Of Airplanes Made Outside U.S., Could Impact Millions Of Customers

B of A Securities analyst Jason Gerberry maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Neutral and raises the price target from $45 to $46.

EXEL

B of A Securities Maintains Neutral on Exelixis, Raises Price Target to $46

In February, the U.S. Food and Drug Administration (FDA) accepted Gilead Sciences, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) New Drug Application (NDA) submissions for lenacapavir — the company&#8217;s twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as pre-<a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">exposure prophylaxis (PrEP)</a>.
What Happened: The FDA will review the applications under priority review and has assigned a Prescription Drug User Fee Act (PDUFA) target <a href="https://www.benzinga.com/pressreleases/25/02/b43780305/u-s-fda-accepts-gileads-new-drug-applications-for-twice-yearly-lenacapavir-for-hiv-prevention-unde" target="_blank" rel="noreferrer noopener">action date of June 19, 2025</a>.
In June 2024, Gilead Sciences shared topline results from an interim analysis of its Phase 3 PURPOSE 1 trial, indicating its twice-yearly lenacapavir&nbsp;demonstrated 100% efficacy for the investigational use of HIV <a target="_blank" href="https://www.benzinga.com/markets/equities/24/06/39416579/why-is-gilead-sciences-stock-trading-higher-on-thursday" rel="noreferrer noopener">prevention in cisgender women</a>.
Based on these results, the independent Data Monitoring Committee (DMC) recommended that Gilead stop the blinded phase of the trial and offer open-label lenacapavir to all participants.
Since June last year, Gilead stock has gained almost 74%, and year-to-date stock has jumped around 21%.
In March, Gilead Sciences&nbsp;presented data from its HIV treatment portfolio and pipeline at the&nbsp;Conference on Retroviruses and&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44283318/gilead-presents-new-hiv-treatment-and-cure-research-data" rel="noreferrer noopener">Opportunistic Infections&nbsp;(CROI 2025)</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44907790/gilead-cancer-drug-combined-with-mercks-drug-effective-in-difficult-to-treat-type-of-breast-cancer" rel="noreferrer noopener">Gilead Cancer Drug Combined With Merck&#8217;s Drug Effective In Difficult To Treat Type Of Breast Cancer</a>
With the breakthrough, Wall Street is paying attention again.
The company, a leader in HIV treatment, is showing signs of a successful turnaround. Despite this momentum, its stock is still relatively cheap, trading at 13.3 times forward earnings — less than the pharmaceutical industry average of 14.
Why It Matters: Some investors may worry that Gilead is repeating history. About 10 years ago, its stock surged due to the success of a cure for hepatitis C, but later, it declined as demand faded. Since then, slow growth and disappointing cancer drug deals hurt its image, making it seem like a value trap.
This time could be different — but Gilead has to deliver.
Over 400,000 Americans use PrEP. To reach $4 billion in annual sales, citing some analysts, the Wall Street Journal <a href="https://www.wsj.com/health/pharma/a-new-shot-prevents-hivand-breathes-new-life-into-a-stagnant-biotech-6badbce9" target="_blank" rel="noreferrer noopener">report</a> expects that by 2030, Gilead must get more people on the drug and grow the market globally. The company aims to more than double U.S. PrEP users to over one million in the next 10 years.
Unlike other drugmakers facing upcoming patent expirations, Gilead is well-positioned. Its HIV drug Biktarvy, used after infection, is protected from generic competition until 2033.
It also has several next-generation HIV treatments in development, supporting its future growth.
In the first quarter of 2025, HIV product sales increased 6% year-over-year <a href="https://www.benzinga.com/general/biotech/25/04/44997817/gilead-sciences-stock-slips-after-mixed-q1-results-lowered-fy25-eps-guidance" target="_blank" rel="noreferrer noopener">to $4.59 billion</a>.
According to a media report in February, the Health and Human Services Department is considering substantial reductions in federal funding for <a href="https://www.benzinga.com/general/biotech/25/03/44395415/trump-administration-weighs-deep-cuts-to-domestic-hiv-prevention-programs-gilead-stock-slides" target="_blank" rel="noreferrer noopener">domestic HIV prevention</a>.
Mitchell Warren, executive director of HIV prevention group AVAC, says the CDC&#8217;s PrEP program could be reduced or cut. Launched last fall as a pilot program, it provides free medication to help prevent HIV.
GILD Price Action: GILD stock is up 2.19% at $111.41 at publication on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/asia/25/06/45791216/citi-to-cut-3500-tech-jobs-in-china-in-global-restructuring-spree" target="_blank" rel="noreferrer noopener">Citi To Cut 3,500 Tech Jobs In China In Global Restructuring Spree</a></li>
</ul>

Photo: Shutterstock

Biotech

Large Cap

Health Care

Movers

Trading Ideas

GILD

Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug

B of A Securities analyst Bradley Sills maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Buy and raises the price target from $215 to $275.

B of A Securities Maintains Buy on MongoDB, Raises Price Target to $275

Deep-pocketed investors have adopted a bearish approach towards GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in GE usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 22 extraordinary options activities for GE Aerospace. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 31% leaning bullish and 63% bearish. Among these notable options, 12 are puts, totaling $794,298, and 10 are calls, amounting to $634,445.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $200.0 to $290.0 for GE Aerospace over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in GE Aerospace's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to GE Aerospace's substantial trades, within a strike price spectrum from $200.0 to $290.0 over the preceding 30 days.
<h3>GE Aerospace Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749143285_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$3.4</td>
<td>$3.35</td>
<td>$3.35</td>
<td>$290.00</td>
<td>$167.8K</td>
<td>578</td>
<td align="right">500</td>
</tr>
<tr>
<td>GE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$5.95</td>
<td>$5.8</td>
<td>$5.81</td>
<td>$240.00</td>
<td>$116.1K</td>
<td>11.7K</td>
<td align="right">468</td>
</tr>
<tr>
<td>GE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$30.8</td>
<td>$30.2</td>
<td>$30.2</td>
<td>$260.00</td>
<td>$105.7K</td>
<td>3</td>
<td align="right">35</td>
</tr>
<tr>
<td>GE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$25.8</td>
<td>$25.45</td>
<td>$25.59</td>
<td>$240.00</td>
<td>$102.3K</td>
<td>911</td>
<td align="right">40</td>
</tr>
<tr>
<td>GE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$10.3</td>
<td>$10.1</td>
<td>$10.3</td>
<td>$250.00</td>
<td>$101.9K</td>
<td>867</td>
<td align="right">200</td>
</tr>
</tbody>
</table>

<h3>About GE Aerospace</h3>
GE Aerospace is the global leader in designing, manufacturing, and servicing large aircraft engines, along with partner Safran in their CFM joint venture. With its massive global installed base of nearly 70,000 commercial and military engines, GE Aerospace earns most of its profits on recurring service revenue of that equipment, which operates for decades. GE Aerospace is the remaining core business of the company formed in 1892 with historical ties to American inventor Thomas Edison; that company became a storied conglomerate with peak revenue of $130 billion in 2000 until GE spun off its appliance, finance, healthcare, and wind and power businesses between 2016 and 2024.
Having examined the options trading patterns of GE Aerospace, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of GE Aerospace</h3>
<ul>
<li>Currently trading with a volume of 1,623,790, the GE's price is up by 0.29%, now at $251.6. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 47 days.</li>
</ul>
<h3>Professional Analyst Ratings for GE Aerospace</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $275.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for GE Aerospace, targeting a price of $275. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest GE Aerospace options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Markets

GE Aerospace Unusual Options Activity For June 05

Deep-pocketed investors have adopted a bullish approach towards RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in RH usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for RH. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 45% leaning bullish and 45% bearish. Among these notable options, 5 are puts, totaling $193,832, and 6 are calls, amounting to $569,925.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $115.0 to $290.0 for RH over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of RH stands at 164.6, with a total volume reaching 558.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in RH, situated within the strike price corridor from $115.0 to $290.0, throughout the last 30 days.
<h3>RH Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749143280_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$32.4</td>
<td>$31.3</td>
<td>$32.4</td>
<td>$160.00</td>
<td>$359.6K</td>
<td align="right">144</td>
<td align="right">111</td>
</tr>
<tr>
<td>RH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/13/25</td>
<td>$7.1</td>
<td>$6.7</td>
<td>$6.7</td>
<td>$200.00</td>
<td>$83.7K</td>
<td align="right">534</td>
<td align="right">11</td>
</tr>
<tr>
<td>RH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/06/25</td>
<td>$25.6</td>
<td>$22.4</td>
<td>$22.4</td>
<td>$200.00</td>
<td>$56.0K</td>
<td align="right">109</td>
<td align="right">37</td>
</tr>
<tr>
<td>RH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$13.1</td>
<td>$12.1</td>
<td>$12.75</td>
<td>$170.00</td>
<td>$38.2K</td>
<td align="right">215</td>
<td align="right">30</td>
</tr>
<tr>
<td>RH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/13/25</td>
<td>$12.6</td>
<td>$11.7</td>
<td>$11.97</td>
<td>$182.50</td>
<td>$35.9K</td>
<td align="right">29</td>
<td align="right">31</td>
</tr>
</tbody>
</table>

<h3>About RH</h3>
RH is a luxury furniture and lifestyle retailer operating in the $136 billion domestic furniture and home furnishing industry. The firm offers merchandise across many categories including furniture, lighting, textiles, bath, decor, and children and is growing the presence of its hospitality business with 22 restaurant locations, including RH Guesthouse. RH innovates, curates, and integrates products, categories, services, and businesses across channels and brand extensions (RH Modern and Waterworks, for example). RH is fully integrated across channels and is positioned to broaden its addressable market over the next decade by expanding abroad, with its World of RH digital platform (highlighting offerings outside of home furnishings), and with offerings in architecture, media, and more.
<h3>RH's Current Market Status</h3>
<ul>
<li>Trading volume stands at 693,990, with RH's price up by 0.3%, positioned at $178.73.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 11 days.</li>
</ul>
<h3>Professional Analyst Ratings for RH</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $193.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Underperform rating for RH, targeting a price of $172. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for RH, targeting a price of $215. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for RH, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Smart Money Is Betting Big In RH Options

Whales with a lot of money to spend have taken a noticeably bullish stance on Alibaba Gr Hldgs.
Looking at options history for Alibaba Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) we detected 49 trades.
If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish expectations and 40% with bearish.
From the overall spotted trades, 9 are puts, for a total amount of $1,134,947 and 40, calls, for a total amount of $2,805,894.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $90.0 to $220.0 for Alibaba Gr Hldgs over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Alibaba Gr Hldgs stands at 7621.44, with a total volume reaching 27,977.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Alibaba Gr Hldgs, situated within the strike price corridor from $90.0 to $220.0, throughout the last 30 days.
<h3>Alibaba Gr Hldgs Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749143275_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BABA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$10.75</td>
<td>$10.7</td>
<td>$10.75</td>
<td>$100.00</td>
<td>$557.9K</td>
<td>4.5K</td>
<td>1.8K</td>
</tr>
<tr>
<td>BABA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$3.85</td>
<td>$3.7</td>
<td>$3.8</td>
<td>$145.00</td>
<td>$496.2K</td>
<td>11.1K</td>
<td>1.3K</td>
</tr>
<tr>
<td>BABA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$11.05</td>
<td>$10.8</td>
<td>$10.85</td>
<td>$100.00</td>
<td>$246.2K</td>
<td>4.5K</td>
<td>232</td>
</tr>
<tr>
<td>BABA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/27/25</td>
<td>$3.95</td>
<td>$3.8</td>
<td>$3.84</td>
<td>$121.00</td>
<td>$153.8K</td>
<td>63</td>
<td>438</td>
</tr>
<tr>
<td>BABA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$15.25</td>
<td>$15.05</td>
<td>$15.1</td>
<td>$120.00</td>
<td>$151.0K</td>
<td>8.2K</td>
<td>252</td>
</tr>
</tbody>
</table>

<h3>About Alibaba Gr Hldgs</h3>
Alibaba is the world's largest online and mobile commerce company as measured by gross merchandise volume. It operates China's online marketplaces, including Taobao (consumer-to-consumer) and Tmall (business-to-consumer). The China commerce retail division is the most valuable cash flow-generating business at Alibaba. Additional revenue sources include China commerce wholesale, international commerce retail/wholesale, local consumer services, cloud computing, digital media and entertainment platforms, Cainiao logistics services, and innovation initiatives/other.
Having examined the options trading patterns of Alibaba Gr Hldgs, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Alibaba Gr Hldgs</h3>
<ul>
<li>With a volume of 10,104,647, the price of BABA is up 0.5% at $120.05. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 70 days.</li>
</ul>
<h3>What The Experts Say On Alibaba Gr Hldgs</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $159.33.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Mizuho persists with their Outperform rating on Alibaba Gr Hldgs, maintaining a target price of $160. 
&#x2A; An analyst from Benchmark has decided to maintain their Buy rating on Alibaba Gr Hldgs, which currently sits at a price target of $176. 
&#x2A; An analyst from Baird has decided to maintain their Outperform rating on Alibaba Gr Hldgs, which currently sits at a price target of $142. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Alibaba Gr Hldgs options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

BABA

Alibaba Gr Hldgs Unusual Options Activity For June 05

WIIM

TSLA

Tesla shares are trading lower as CEO Elon Musk criticizes President Trump's tax-cut bill online. The proposed legislation would cut EV and residential solar tax credits that help the company generate profits and would add an annual $250 fee on EV drivers.

<h3>Gainers</h3>
<ul>
<li>Newegg Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) shares moved upwards by 64.0% to $10.3 during Thursday's regular session. The company's market cap stands at $200.6 million. </li>
<li>Cheetah Net Supply Chain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) shares increased by 36.97% to $1.95. The market value of their outstanding shares is at $6.2 million. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGA#NASDAQ">QVCGA</a>) shares rose 28.03% to $2.9. The market value of their outstanding shares is at $23.3 million. </li>
<li>Yunji (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YJ#NASDAQ">YJ</a>) shares moved upwards by 19.97% to $2.04. The market value of their outstanding shares is at $40.1 million. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGP#NASDAQ">QVCGP</a>) shares moved upwards by 18.28% to $8.15. </li>
<li>51 Talk Online Education (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/COE#AMEX">COE</a>) stock increased by 16.59% to $25.65. The company's market cap stands at $146.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mullen Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) stock fell 33.5% to $10.71 during Thursday's regular session. The market value of their outstanding shares is at $5.7 million. </li>
<li>BARK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BARK#NYSE">BARK</a>) stock declined by 27.6% to $0.98. The market value of their outstanding shares is at $170.9 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Jiade (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) stock declined by 23.9% to $0.43. The market value of their outstanding shares is at $10.5 million. </li>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) shares decreased by 19.6% to $47.6. The company's market cap stands at $33.2 million. </li>
<li>PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) stock declined by 17.74% to $66.47. The market value of their outstanding shares is at $3.6 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Duluth Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTH#NASDAQ">DLTH</a>) stock fell 15.18% to $1.9. The market value of their outstanding shares is at $69.5 million. As per the press release, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BARK

CTNT

DLTH

JDZG

MULN

NEGG

QVCGA

QVCGP

SBET

12 Consumer Discretionary Stocks Moving In Thursday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Brag House Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBH#NASDAQ">TBH</a>) stock moved upwards by 63.2% to $0.97 during Thursday's regular session. The market value of their outstanding shares is at $10.5 million. </li>
<li>Reading Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDIB#NASDAQ">RDIB</a>) stock moved upwards by 16.56% to $13.23. The market value of their outstanding shares is at $297.3 million. </li>
<li>GDEV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDEV#NASDAQ">GDEV</a>) shares moved upwards by 14.74% to $18.75. The company's market cap stands at $339.5 million. </li>
<li>Antelope Ent Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) shares rose 13.98% to $2.27. The market value of their outstanding shares is at $7.7 million. </li>
<li>iHeartMedia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IHRT#NASDAQ">IHRT</a>) stock rose 13.82% to $1.6. The market value of their outstanding shares is at $236.9 million. </li>
<li>Creative Realities (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREX#NASDAQ">CREX</a>) shares increased by 12.77% to $3.53. The market value of their outstanding shares is at $37.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CTRL Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCTR#NASDAQ">MCTR</a>) shares decreased by 56.2% to $6.75 during Thursday's regular session. The company's market cap stands at $103.2 million. </li>
<li>EPWK Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPWK#NASDAQ">EPWK</a>) stock declined by 25.09% to $6.78. The market value of their outstanding shares is at $151.3 million. </li>
<li>K Wave Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWM#NASDAQ">KWM</a>) stock declined by 21.52% to $3.52. The company's market cap stands at $222.3 million. </li>
<li>LZ Technology Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZMH#NASDAQ">LZMH</a>) stock fell 11.14% to $21.39. The company's market cap stands at $3.2 billion. </li>
<li>CuriosityStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURI#NASDAQ">CURI</a>) stock declined by 10.74% to $5.83. The market value of their outstanding shares is at $334.7 million. </li>
<li>Asset Entities (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>) stock decreased by 10.57% to $6.92. The market value of their outstanding shares is at $109.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEHL

ASST

CREX

CURI

EPWK

GDEV

IHRT

LZMH

MCTR

RDIB

12 Communication Services Stocks Moving In Thursday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) shares rose 72.7% to $3.99 during Thursday's regular session. The company's market cap stands at $57.2 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares rose 57.35% to $20.0. The company's market cap stands at $534.2 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares rose 43.26% to $2.98. The company's market cap stands at $8.5 million. </li>
<li>I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) stock rose 39.16% to $2.49. The company's market cap stands at $201.4 million. </li>
<li>Kronos Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRON#NASDAQ">KRON</a>) shares rose 28.34% to $0.87. The market value of their outstanding shares is at $52.8 million. </li>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) stock increased by 23.8% to $2.6. The company's market cap stands at $12.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock declined by 58.9% to $1.34 during Thursday's regular session. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares fell 46.9% to $0.77. The market value of their outstanding shares is at $18.2 million. </li>
<li>Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) stock declined by 33.27% to $1.57. The company's market cap stands at $51.4 million. </li>
<li>Lyell Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYEL#NASDAQ">LYEL</a>) stock declined by 25.32% to $10.06. The company's market cap stands at $148.9 million. </li>
<li>Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) stock declined by 15.93% to $8.47. The company's market cap stands at $425.1 million. </li>
<li>Hoth Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) shares decreased by 15.7% to $1.29. The company's market cap stands at $17.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CBUS

CYCC

EYEN

HOTH

HSDT

IMAB

KRON

LIMN

LYEL

MODV

PHIO

RGNX

12 Health Care Stocks Moving In Thursday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>ZenaTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#NASDAQ">ZENA</a>) shares moved upwards by 74.6% to $5.55 during Thursday's regular session. The company's market cap stands at $141.5 million. </li>
<li>Alpha Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATGL#NASDAQ">ATGL</a>) stock rose 30.79% to $35.0. The company's market cap stands at $576.1 million. </li>
<li>Brand Engagement Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) stock increased by 20.47% to $0.52. The company's market cap stands at $21.6 million. </li>
<li>Digital Turbine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) shares moved upwards by 13.2% to $5.01. The market value of their outstanding shares is at $526.6 million. </li>
<li>MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) stock increased by 13.02% to $225.74. The market value of their outstanding shares is at $18.4 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>Castellum (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CTM#AMEX">CTM</a>) stock moved upwards by 12.37% to $1.14. The market value of their outstanding shares is at $97.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BitMine Immersion Technologies, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#AMEX">BMNR</a>) stock fell 61.3% to $7.36 during Thursday's regular session. </li>
<li>Foxx Development Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXX#NASDAQ">FOXX</a>) stock declined by 18.85% to $4.5. The market value of their outstanding shares is at $30.5 million. </li>
<li>CoreWeave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) stock decreased by 15.43% to $137.95. The market value of their outstanding shares is at $66.2 billion. </li>
<li>FiEE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MINM#NASDAQ">MINM</a>) stock fell 14.05% to $3.0. The company's market cap stands at $22.0 million. </li>
<li>Ciena (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) shares fell 13.78% to $72.33. The company's market cap stands at $10.2 billion. As per the news, the Q2 earnings report came out today. </li>
<li>Optical Cable (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCC#NASDAQ">OCC</a>) stock decreased by 11.56% to $2.79. The company's market cap stands at $22.9 million. As per the news, the Q2 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APPS

ATGL

BMNR

BNAI

CIEN

CRWV

FOXX

MINM

12 Information Technology Stocks Moving In Thursday's Intraday Session

B of A Securities analyst Melanie Nunez maintains Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) with a Underperform and raises the price target from $78 to $93.

FIVE

B of A Securities Maintains Underperform on Five Below, Raises Price Target to $93

Treace Medical Concepts, Inc.&nbsp;("Treace" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship&nbsp;<a href="https://www.globenewswire.com/Tracker?data=PhrvPgwWnFGurg6S4cTMXPnZSvIbsh-7vD75qshZf4W2Rv0eH6iYS-TAky5-84_Ri0VIN7nTuV0z-GkegYiluBakImmk3Zj1w4rROHMt6lwsw3REO81rw-etukNCmXZSin4tSCCkNkE0xBHrq0Q7tPjokuA-oap_BjbHuXsRo-LgNNZoGsnUePUbT2-ILzChf2DHLwrSQXQZyWVQvrJEbk0AQHM7eVsk7zC4vaKtqUoeoDHCJzOqPhWKcqtvWnTInYG_aeXX0i81qxfMgqiVsg==">Lapiplasty</a><a href="https://www.globenewswire.com/Tracker?data=LrnJlF18b7EWzk_EAUJaWxGrxsoWgQpX1WKeJ0MipgVBshUVXHUA5zPh5NCDgcNKBO6A9xD35YFbiyZ1DNTulkO1cYzusFeKbXuLEM4blCZJ5k744h9h6kzAVfgox0FPgavIE7DwiF422KNrSWJFHx01V7TfoKgoah7rt5AC07IhZmYAf7CbRDc1QqTt8wwbr56hBQaud9XD_58LlCi_nMcPOnTeqG5Lb_IyWD8AxttJPAbLBRIxrVfgQTACvnytyRl4MFQiNTFTY4mRBRbg-Q==">&#xAE;</a>&nbsp;and&nbsp;<a href="https://www.globenewswire.com/Tracker?data=Ky8kGGLXsMTu3wsAXQppn1PfeewfClEbXAZbmmoTmTGzckwETGDKjrRCVtjW_PfjE682okBcjHwSpyYD3ZLTWqlyvmlQaTncmuRanfcgyPXq89flAjVvT8U90c9JXN3ZHl_RVYLNeeXD1fy3lK0reILVhp40trP0SNtWir-Im2LoRiGF6hZmEkTIaoQWpTaJNiiAU3_p36gcE7q72b6FYhsIHMJpXu4rMIRqg6AB3B4p9xhKAjU7aR8hF3ED29goR3-pfMcJotTJpuPXNubY4swADMFv4kvo1u9e-PuH6H034oUlBGOBo8pbqcqr6pHY">Adductoplasty</a><a href="https://www.globenewswire.com/Tracker?data=iU3fmGaUZi_JeR470Lioedud-n-0b_bx4qOO-3b22Rvo4Xdt1yz_PqYHunQivstC8HxZtcFDnANwN5nPFT05HigJ0nSJBwn0LnMVL0ugniZAkJRYpK-63l0Qn7aWa0elJwsd5hZielGaxqcGOfBP6MtE2xeJMav5md3UhP8ioZkA0CQNWbieFy6sUjXGNl9yCVNuhlpeg58_DWgp2zGQCrNi8j1JTY2kOFmxR0GJ6TFclq7OrROrzjUrDqYhpUNd3NzdJg9mJf7bHMrBObB4dtCB4BQHRme_eeVBW5QPZ4w=">&#xAE;</a>&nbsp;procedures, today announced that it filed a lawsuit against&nbsp;Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. (collectively, "Zimmer") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>), alleging infringement of 4 patents related to Treace's innovative Lapiplasty&#xAE; 3D Bunion Correction&#xAE; technologies. The suit was filed in the&nbsp;United States District Court for the District of Delaware, and seeks injunctive relief and damages.

TMCI

Treace Medical Concepts Files Patent Infringement Lawsuit Against Zimmer Biomet And Paragon 28, Alleging Violation Of 4 Patents Related To Its Lapiplasty 3D Bunion Correction Technologies And Seeking Injunctive Relief And Damages

Company announces 2028 financial targets
Top-line growth target supported by March 31 backlog of $14.6 billion
Transformative margin expansion underway
Oshkosh Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>), a leading innovator of purpose-built vehicles and equipment, shared its strategy for growth and 2028 financial targets at its <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Foshkosh-2025-investor-day.open-exchange.net%2Fregistration&amp;esheet=54266669&amp;newsitemid=20250605834205&amp;lan=en-US&amp;anchor=Investor+Day&amp;index=1&amp;md5=586a401f55d046b1ede96759f92450cb">Investor Day</a> held June 5, 2025. The Company announced the following 2028 consolidated financial targets:
<ul>
<li>$13 billion-$14 billion revenue</li>
<li>12%-14% adjusted1 operating income margin</li>
<li>$18.00-$22.00 adjusted1 earnings per share</li>
<li>90%+ free cash flow conversion2 across the cycle</li>
</ul>

Guidance

Oshkosh Projects 2028 Revenue of $13B-$14B And Adj. EPS Of $18.00-$22.00

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) recent price consolidation is raising alarms about whether the $100,000 <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45790623/bitcoin-at-105000-bull-market-correction-or-bear-market-beginning">support level will hold</a>. 
What Happened: In an <a href="https://www.youtube.com/watch?v=G10hBqONoXg">episode</a> of the Technical Roundup podcast, pseudonymous trader DonAlt explained that while the monthly chart remains strongly bullish, the daily timeframe is looking shaky. 
While Bitcoin&#8217;s monthly chart remains &#8220;ragingly bullish&#8221; with strong support between $94,000-$102,000, the daily timeframe shows more concerning patterns. 
He pointed to a false breakout above resistance that's since been rejected, adding, the daily is a little bit choppy, if not leaning slightly bearish.
DonAlt considers $100,000 a clear line in the sand: If you're bullish, you've got a clean invalidation at $100,000. If it breaks, I think we're looking at a fast trip to $90,000 again.
Despite short-term caution on Bitcoin, DonAlt expressed renewed optimism on Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), calling the recent breakout "sexy" after months of lagging behind.
ETH has reclaimed key support on the ETH/BTC pair and bounced ~8–10%, suggesting growing momentum. He expects a rotation out of altcoins like Solana into ETH, noting ETH has outperformed peers for six to seven consecutive weeks.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45790623/bitcoin-at-105000-bull-market-correction-or-bear-market-beginning">Bitcoin At $105,000: Bull Market Correction Or Bear Market Beginning?</a>
What's Next: Looking ahead, DonAlt warned about potential risks from leveraged corporate Bitcoin positions, particularly Strategy&#8217;s aggressive accumulation strategy.
&#8220;The moment that that starts unraveling like Bitcoin is going to go down like 50%ish I think at least,&#8221; he cautioned, though he believes &#8220;we&#8217;re not there yet.&#8221;
The trader has adjusted his strategy for this cycle, taking profits gradually rather than attempting to time a perfect exit. 
&#8220;I&#8217;m not young enough anymore to stay up and look at the chart 24/7 just to make sure that I get the top,&#8221; he admitted, describing his more conservative approach as allowing him to &#8220;go on a vacation for a week&#8221; and not care about market movements.
What's Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45789332/bitcoin-ethereum-xrp-dogecoin-dip-but-trader-says-everythings-going-according-to-plan">Bitcoin, Ethereum, XRP, Dogecoin Dip, But Trader Says Everything&#8217;s Going According to Plan</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

Could Bitcoin Plummet To $90,000 Soon?

Rosenblatt analyst Catharine Trebnick maintained Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) with a Buy and a&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/CXM/analyst-ratings" rel="noreferrer noopener">$12&nbsp;price target</a> on Thursday.
Sprinklr&#8217;s results demonstrated progress and its ongoing transformation, Trebnick said. The company reported: 
<ul class="wp-block-list">
<li>Total revenue of $205.5 million (+5% Y/Y), beating the Street estimate of $201.8 million and coming in above guidance of $201.5 million-$202.5 million.</li>
<li>A 4% Y/Y increase in Subscription revenue to $184.1 million, surpassing consensus estimates by $1 million and generating 90% of total revenue, he said.</li>
<li>Professional services revenue was $21.4 million, up 15% Y/Y (versus 18% Q/Q), beating Trebnick&#8217;s estimate by ~$2 million.</li>
<li>Operating income of $36.7 million (18% margin), exceeding the analyst estimate of $32.3 million (16% margin) and above guidance of $31.5 million-$32.5 million,</li>
<li>Adjusted EPS of 12 cents, which beats the Street estimate of 10 cents.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/markets/small-cap/25/06/45770622/sprinklr-rises-on-solid-earnings-raised-outlook-and-new-150-million-buyback-plan" target="_blank" rel="noreferrer noopener">Sprinklr Rises On Solid Earnings, Raised Outlook, And New $150 Million Buyback Plan</a>
Trebnick says the company grapples with elevated customer churn and down-sell activity, which has persisted over the past 24 months. 
NRR declined to 102% from 104% last quarter. This trend reflects ongoing customer churn and down-sell activity due to inconsistent operational execution, ineffective implementations, and accumulated technical debt. 
While customers generating over $1 million in subscription revenue grew 6% Y/Y to 146, the Q/Q decline from 149 reflects customers falling below the $1 million threshold amid limited renewals and reduced up-sell/cross-sell activity.
Management has prioritized churn reduction through the &#8220;Project Bear Hug&#8221; initiative, which has engaged over 200 of its top 500 customers and is showing tangible traction. To enhance customer success, management has also standardized implementation processes to 80% consistency, he said. 
This comprehensive go-to-market overhaul, including new sales pod structures and enablement programs, is expected to gain momentum in the second half of 2026 and position Sprinklr for potential acceleration in fiscal 2027 and 2028, Trebnick said.
These early proof points and management&#8217;s ability to deliver solid financial results while executing strategic initiatives encouraged the analyst.
Trebnick projected second-quarter revenue of $205.5 million and EPS of $0.10.
Price Action: CXM shares are up 0.55% at $9.11 at the last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/06/45789800/amd-acquires-another-company-to-expands-ai-arsenal" target="_blank" rel="noreferrer noopener">AMD Acquires Another Company To Expand AI Arsenal</a></li>
</ul>
Image: Shutterstock

Reiteration

Sprinklr Eyes Long-Term Growth With 'Project Bear Hug' Despite Customer Churn Concerns: Analyst

ULTA

CNBC Halftime Report Final Trades: GAP, Ulta Beauty, Walt Disney Company, iShares Silver Trust

Press Releases

Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025

Earnings

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit

Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

Veru Participates in a Virtual Investor KOL Connect Segment

JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next Level

Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

Comments

Veru

Noticias

Últimas noticias sobre Veru (NASDAQ:VERU) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL